Hospital

In recent years, telestroke services have transformed stroke care delivery, especially in rural or underserved areas.

Pharmacists play an important role in managing patients with this complex condition.

Community accessibility and specialized training in effective medication counseling make pharmacists a valuable resource in helping address injectable biologic hesitancy.

The study may serve as a foundation for future investigation regarding dietary recommendations to support the treatment of Alzheimer disease.

The autologous, fully human CD19 chimeric antigen receptor T-cell product, KYV-101, is being studied for the treatment of patients with progressive myasthenia gravis.

Risk of developing anxiety or depression is highest within the first year after cardiovascular hospitalization.

The systematic review summarized all available evidence on the subject, finding that intravenous immunoglobulin could have a role in treatment.

Palopegteriparatide is a prodrug of parathyroid hormone designed to provide continuous exposure of the hormone over a 24-hour dosing period.

Many patients are unaware of wound complication, so it is valuable for pharmacists to communicate prevention methods with all patients with diabetes.

The use of CGMs in pregnancy provides clinicians with essential data in real-time, rather than a snapshot given by traditional finger stick testing.

The commencement of the phase 1 clinical trial of SAT-3247 is expected in Q3 of 2024.

Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.

Findings from 2 large datasets suggest hormone therapy may reduce Alzheimer risk, hippocampal atrophy, and cerebrovascular disease.

The study is expected to include 460 individuals that will be randomly treated with 12mg of ifinatamab deruxtecan or chemotherapy chosen by the health care provider.

A number of asthma-related emergency room visits are a result of viruses, but certain airborne pollens—notably Cupressaceae and tree pollens—are also contributors.

Dan Schrum discusses the integral role of pharmacy specialists in translating clinical trial results to clinical practice.

The findings may lead to the development of diagnostic and therapeutic targets to prevent worsening disease in patients.

neffy is an epinephrine nasal spray for the emergency treatment of allergic reactions in adults and pediatric patients.

Isatuximab (Sarclisa; Sanofi) in combination with standard-of-care significantly improved progression-free survival in patients with newly diagnosed multiple myeloma.

The primary end point of clinical remission at week 26 was met, with 36.7% of individuals treated with RHB-104 achieving clinical remission.

Intravenous Immunoglobulin as a therapy for patients with pyoderma gangrenosum could open new treatment avenues for the rare and challenging condition.

Dan Schrum highlights the crucial role of lymphodepletion in enhancing the effectiveness of CAR T cell therapy.

The injection adds an additional option to address emergency known or suspected opioid overdoses.

The indication is for the reduction of proteinuria in adult patients who have primary immunoglobulin A nephropathy and are at risk of disease progression.

Significant commonalities between type 2 diabetes and neurodegenerative disorders suggest that treatments effective for one condition may benefit the other.

Acalabrutinib plus venetoclax, with or without obinutuzumab, demonstrated significant improvements in progression-free survival.

CD38 density may indicate the efficacy of monoclonal antibody treatment in patients with multiple myeloma.

Sunobinop binds to and activate nociception/orphanin-FQ peptide receptor, which is a known therapeutic target for substance use disorder.

A report from SkyQuest Technology highlights the growth in the oncology and insulin spaces, indicating they will contribute to the most growth.

The drug also receives orphan drug designation for the treatment of pancreatic neuroendocrine tumors and a Prescription Drug User Fee Act target action date of April 3, 2025.